- Home
- EXAS vs OWL Comparison
EXAS vs OWL Comparison
Compare EXAS & OWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- OWL
- Stock Information
- Founded
- EXAS 1995
- OWL 2020
- Country
- EXAS United States
- OWL United States
- Employees
- EXAS N/A
- OWL N/A
- Industry
- EXAS Medical Specialities
- OWL Investment Managers
- Sector
- EXAS Health Care
- OWL Finance
- Exchange
- EXAS Nasdaq
- OWL Nasdaq
- Market Cap
- EXAS 11.0B
- OWL 10.6B
- IPO Year
- EXAS N/A
- OWL N/A
- Fundamental
- Price
- EXAS $100.87
- OWL $13.70
- Analyst Decision
- EXAS Strong Buy
- OWL Buy
- Analyst Count
- EXAS 18
- OWL 15
- Target Price
- EXAS $72.44
- OWL $22.50
- AVG Volume (30 Days)
- EXAS 7.2M
- OWL 17.0M
- Earning Date
- EXAS 11-03-2025
- OWL 10-30-2025
- Dividend Yield
- EXAS N/A
- OWL 6.55%
- EPS Growth
- EXAS N/A
- OWL 47.85
- EPS
- EXAS N/A
- OWL 0.08
- Revenue
- EXAS $3,082,033,000.00
- OWL $2,745,943,000.00
- Revenue This Year
- EXAS $16.68
- OWL $17.06
- Revenue Next Year
- EXAS $12.36
- OWL $21.21
- P/E Ratio
- EXAS N/A
- OWL $177.21
- Revenue Growth
- EXAS 14.47
- OWL 27.24
- 52 Week Low
- EXAS $38.81
- OWL $13.25
- 52 Week High
- EXAS $101.87
- OWL $26.73
- Technical
- Relative Strength Index (RSI)
- EXAS 91.11
- OWL 30.43
- Support Level
- EXAS $66.00
- OWL $13.25
- Resistance Level
- EXAS $69.08
- OWL $14.39
- Average True Range (ATR)
- EXAS 3.80
- OWL 0.72
- MACD
- EXAS 2.49
- OWL -0.14
- Stochastic Oscillator
- EXAS 97.30
- OWL 13.45
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About OWL Blue Owl Capital Inc.
Blue Owl Capital Inc is an alternative asset management firm. The company deploys private capital across Credit, GP Strategic Capital, and Real Estate platforms on behalf of institutional and private wealth clients. The company conducts its operations through Blue Owl Capital Holdings LP (Blue Owl Holdings) and Blue Owl Capital Carry LP (Blue Owl Carry). Its investor base includes a diversified mix of institutional investors, including public and private pension funds, endowments, foundations, family offices, private banks, high-net-worth individuals, asset managers, and insurance companies. The company generates substantially all of its revenues in the United States.